Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JYP0035 + fulvestrant
- Development stage
- Unknown
- Lead developer
- Guangzhou JOYO Pharma Co., Ltd
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
JYP0035 + fulvestrant is an investigational combination therapy being developed by Chengdu JOYO Pharma for the treatment of advanced breast cancer. The regimen consists of JYP0035, a small molecule inhibitor of the alpha isoform of phosphoinositide 3-kinase (PI3Kα), and fulvestrant, a selective estrogen receptor degrader (SERD). This combination is specifically targeted at patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer that harbors PIK3CA mutations and has progressed on prior endocrine therapy. By simultaneously inhibiting the PI3K/AKT/mTOR pathway and degrading the estrogen receptor, the therapy aims to counteract crosstalk between these pathways that often leads to treatment resistance. It is currently being evaluated in Phase III clinical trials.
- Other names
- JYP0035 plus fulvestrantJYP-0035 plus fulvestrantJYP 0035 plus fulvestrant
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)ESR1 (ERα)
Beyond the preview
Go deeper on JYP0035 + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JYP0035 + fulvestrant.